ACTICCA-1
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
- NCT02170090 ↗
- Active, not recruiting
- Universitätsklinikum Hamburg-Eppendorf
- Deep
We haven't built an HCP commentary report on ACTICCA-1 (gemcitabine plus cisplatin in biliary tract cancer after curative intent resection) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from the 30 newest of 31 indexed sources (May 2021 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether cisplatin and gemcitabine offer meaningful benefit in the adjuvant setting
- Whether the findings should change adjuvant treatment practice
- Which patients, if any, may benefit more from cisplatin and gemcitabine
- Whether new or biomarker-directed adjuvant strategies are needed
Also discussed: preserving first-line treatment options.
Indexed commentary on ACTICCA-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 29 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Cholangiocarcinoma; Gall Bladder Carcinoma
- Interventions
- Gemcitabine; Cisplatin; Capecitabine
- Arms
- Gemcitabine plus Cisplatin · Experimental
- Capecitabine · Active comparator
- Enrollment
- 789
- Primary outcomes
- Disease free survival (DFS)
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf with Deutsche Krebshilfe e.V., Bonn (Germany), Cancer Research UK, Australasian Gastro-Intestinal Trials Group, Dutch Cancer Society
- Start
- Apr 2014
- Primary completion
- Dec 2025 (estimated)
- Results posted
- No
- Registry record
- NCT02170090 · updated Mar 30, 2025
Publications
linked from the registry- Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klumpen HJ, Lohse AW, Nashan B, Primrose J, Schrum S, Shannon J, Vettorazzi E, Wege H. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015 Jul 31;15:564. doi: 10.1186/s12885-015-1498-0. PubMed 26228433